Abstract
The reliability of cerebrospinal fluid (CSF) biomarkers biomarkers in reflecting the rate of cognitive decline in patients with Alzheimer's Disease (AD) is still controversial (Williams et al., 2011). Our study aimed to correlate CSF biomarkers, MTL atrophy, cerebral white matter disease, and cognitive performance in patients diagnosed with AD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
